Entries by Linda
Genoptix’s Immuno-Oncology Testing Now Covers Additional Tumor Types
Tests Can Identify More Cancer Patients Eligible for Merck’s KEYTRUDA® Therapy CARLSBAD, Calif., July 6, 2017 — Genoptix, Inc., a leading oncology diagnostics laboratory and informatics company, today announced that it offers three diagnostic tests that support immunotherapy decisions for solid tumor cancers. The tests include a companion diagnostic test for PD-L1 22C3 pharmDx, plus […]
Ampersand Capital Partners and 1315 Capital Close Transaction to Acquire Genoptix
Experienced management team co-invests with leading private investors to acquire premier oncology diagnostics and informatics services company CARLSBAD, Calif., March 7, 2017 — An experienced management team, led by Joseph M. Limber, in partnership with Ampersand Capital Partners and 1315 Capital, has completed the acquisition of Genoptix, Inc. from Novartis. The financial terms of the transaction are not […]
Recent News
- NeoGenomics Completes Acquisition of Genoptix, Inc.December 10, 2018 - 9:00 am
- NeoGenomics Signs Definitive Agreement to Acquire GenoptixOctober 23, 2018 - 9:00 am
- Genoptix Launches FDA-Authorized BCR-ABL MRDx® TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna® (nilotinib)September 4, 2018 - 8:30 am
HOURS OF OPERATION
Our lab is open six days a week:
5:00am to 6:00pm PT Mon-Fri
7:00am to 3:30pm PT Saturday
For after-hours assistance, your call
will be connected with an on-duty
Client Services Representative.
